Key Points
- Zachary Roberts, EVP of Allogene Therapeutics, sold 26,269 shares on January 21 at an average price of $1.56, receiving about $40,980, and his holdings fell 4.08% to 616,866 shares (valued ~ $962,311).
- ALLO trades near $1.72 with a market cap of about $386.5M, recently reported EPS of -$0.19 (beating estimates), has heavy institutional ownership (~83.6%) including large additions by Goldman Sachs and Jane Street, and carries a consensus "Moderate Buy" rating with a $8.40 target.
Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) EVP Zachary Roberts sold 26,269 shares of the company's stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $1.56, for a total value of $40,979.64. Following the sale, the executive vice president owned 616,866 shares of the company's stock, valued at approximately $962,310.96. The trade was a 4.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Allogene Therapeutics Stock Performance
Shares of NASDAQ ALLO opened at $1.72 on Friday. The stock has a market capitalization of $386.54 million, a P/E ratio of -1.76 and a beta of 0.51. The stock's fifty day moving average is $1.46 and its 200 day moving average is $1.30. Allogene Therapeutics, Inc. has a 52 week low of $0.86 and a 52 week high of $3.78.
Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.04. Equities research analysts forecast that Allogene Therapeutics, Inc. will post -1.28 earnings per share for the current year.
Institutional Investors Weigh In On Allogene Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of ALLO. AQR Capital Management LLC bought a new position in Allogene Therapeutics in the first quarter valued at about $85,000. Goldman Sachs Group Inc. grew its holdings in shares of Allogene Therapeutics by 177.9% during the first quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company's stock worth $8,547,000 after purchasing an additional 3,747,397 shares during the last quarter. Jane Street Group LLC increased its stake in shares of Allogene Therapeutics by 578.7% in the first quarter. Jane Street Group LLC now owns 1,116,681 shares of the company's stock valued at $1,630,000 after buying an additional 952,158 shares during the period. Bourgeon Capital Management LLC bought a new position in Allogene Therapeutics in the 2nd quarter valued at approximately $124,000. Finally, Vanguard Personalized Indexing Management LLC boosted its position in Allogene Therapeutics by 183.5% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 71,688 shares of the company's stock worth $81,000 after buying an additional 46,398 shares during the period. Institutional investors own 83.63% of the company's stock.
Wall Street Analysts Forecast Growth
A number of brokerages recently issued reports on ALLO. Wall Street Zen raised shares of Allogene Therapeutics from a "sell" rating to a "hold" rating in a research note on Friday, November 28th. JPMorgan Chase & Co. reiterated an "underweight" rating on shares of Allogene Therapeutics in a research note on Friday, October 10th. Weiss Ratings restated a "sell (e+)" rating on shares of Allogene Therapeutics in a research report on Wednesday, October 8th. Citigroup raised Allogene Therapeutics from a "market perform" rating to an "outperform" rating in a research note on Friday, January 9th. Finally, Citizens Jmp raised Allogene Therapeutics from a "market perform" rating to an "outperform" rating and set a $5.00 target price for the company in a research note on Friday, January 9th. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $8.40.
View Our Latest Research Report on Allogene Therapeutics
Allogene Therapeutics Company Profile
(
Get Free Report)
Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.
The company's pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
